annb0t
Top 20
MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- Cabazitaxel (Jevtana, Sanofi) is a market leading chemotherapy for the treatment of advanced prostate cancer (mCRPC). Developed by Australian biotech company Starpharma, DEP® cabazitaxel is a patented, highly water soluble dendrimer nanoparticle version of standard cabazitaxel which has shown, in preclinical and clinical studies, benefits in terms of safety and efficacy. Positive Efficacy and Safety results for DEP® cabazitaxel in...
>>> Read more: Starpharma presents compelling data in Prostate Cancer at ESMO
>>> Read more: Starpharma presents compelling data in Prostate Cancer at ESMO
